BIOGl Stock Overview
A closed ended equity mutual fund launched by Frostrow Capital LLP.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
The Biotech Growth Trust PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£9.47 |
| 52 Week High | UK£10.38 |
| 52 Week Low | UK£7.20 |
| Beta | 0.50 |
| 1 Month Change | 1.18% |
| 3 Month Change | -6.05% |
| 1 Year Change | 15.63% |
| 3 Year Change | -30.37% |
| 5 Year Change | 36.06% |
| Change since IPO | 15.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOGl | GB Capital Markets | GB Market | |
|---|---|---|---|
| 7D | -3.2% | 1.2% | -1.3% |
| 1Y | 15.6% | 12.7% | 6.9% |
Return vs Industry: BIOGl exceeded the UK Capital Markets industry which returned 12.7% over the past year.
Return vs Market: BIOGl exceeded the UK Market which returned 6.9% over the past year.
Price Volatility
| BIOGl volatility | |
|---|---|
| BIOGl Average Weekly Movement | 3.7% |
| Capital Markets Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: BIOGl has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOGl's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | n/a | www.biotechgt.com/index.php/biog/home/overview/ |
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe.
The Biotech Growth Trust PLC Fundamentals Summary
| BIOGl fundamental statistics | |
|---|---|
| Market cap | UK£315.89m |
| Earnings (TTM) | -UK£92.02m |
| Revenue (TTM) | n/a |
-3.6x
P/S Ratio-3.4x
P/E RatioIs BIOGl overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOGl income statement (TTM) | |
|---|---|
| Revenue | -UK£87.65m |
| Cost of Revenue | UK£0 |
| Gross Profit | -UK£87.65m |
| Other Expenses | UK£4.37m |
| Earnings | -UK£92.02m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Jun 05, 2024
| Earnings per share (EPS) | -2.76 |
| Gross Margin | 100.00% |
| Net Profit Margin | 104.99% |
| Debt/Equity Ratio | 3.9% |
How did BIOGl perform over the long term?
See historical performance and comparison